Conflicting QSSD definitions from two federal agencies mean that CMS’ administrative authority on drug pricing and payment is ...

Strengthened Balance Sheet - On March 18, 2025, the Company completed a public equity financing for gross proceeds of approximately $201.2 million, before deducting fees and expenses. The Company ...

Biohaven Ltd. (NYSE: BHVN) (Biohaven or the Company), a global clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of life-changing therapies to treat ...

Trump's executive order sets a deadline for drugmakers to lower the cost of prescription drugs in the U.S. or face new limits ...

The Food and Drug Administration (FDA) recently announced that it had identified “significant data integrity and study conduct concerns” ...

The majority of RNAs in each of our cells don't code for any of the thousands of proteins that make up our bodies. Instead, ...

A photograph with a notorious figure may be behind the Trump administration's refusal to grant a top international politician ...

Trump's order seeks to ease regulations to compel more U.S. drug manufacturing. He also plans to assess tariffs on drug ...

Using advanced artificial intelligence, researchers have developed a novel method to make drug development faster and more ...

Ireland’s Health and Safety Executive has criticised a new report revealing the country’s shocking last place in Western Europe for new oncology drug access.

IND application submission on track for Q2 2025: MBX 4291, a GLP-1/GIP co-agonist prodrug, is being developed as a once-monthly treatment for obesity. The Company expects to submit an IND application ...